房颤患者PCI术后抗栓治疗:2021年北美共识更新
该文件为北美共识声明2018版的重点更新,针对接受PCI的房颤患者,推荐非维生素K拮抗剂口服抗凝药作为首选口服抗凝,围PCI期用双联抗血小板,其后默认改为P2Y12抑制剂(优选氯吡格雷)联合NOAC的双联治疗,高血栓风险者可三联治疗至1个月,双联治疗6-12个月后单用口服抗凝。
要点
- 房颤PCI患者首选NOAC作为口服抗凝药。
- 围PCI期用阿司匹林加P2Y12抑制剂双联抗血小板。
- 默认策略为停阿司匹林,用P2Y12抑制剂(优选氯吡格雷)联合NOAC。
核心结论
- 房颤PCI患者首选NOAC作为口服抗凝,围PCI期用双联抗血小板,其后默认改为P2Y12抑制剂联合NOAC的双联治疗。
研究设计与样本
- 北美共识声明2018版的重点更新,基于2018年后发表的该领域关键临床试验。
关键数值与推荐
- 围PCI期(住院期间、出院前、PCI后至多1周,由治疗医生决定)给予阿司匹林加P2Y12抑制剂双联抗血小板。
- 其后默认停阿司匹林,继续P2Y12抑制剂(优选氯吡格雷)联合NOAC的双联治疗。
- 血栓风险增加且出血风险可接受者,可继续阿司匹林(三联治疗)至多1个月。
- 双联治疗持续6至12个月,实际时长取决于患者缺血与出血风险。
- 双联治疗结束后停抗血小板,单用口服抗凝。
临床怎么用
- 房颤PCI患者口服抗凝首选NOAC而非维生素K拮抗剂。
- 围PCI期用双联抗血小板,其后默认转为P2Y12抑制剂联合NOAC的双联治疗。
- 高血栓风险且出血风险可接受者,三联治疗可至1个月。
- 双联治疗6-12个月后停抗血小板,单用口服抗凝。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing PCI require oral anticoagulation for the prevention of cardiac thromboembolism and dual antiplatelet therapy for the prevention of coronary thrombotic complications. The combination of oral anticoagulation and dual antiplatelet therapy substantially increases the risk of bleeding. Over the last decade, a series of North American Consensus Statements on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention have been reported. Since the last update in 2018, several pivotal clinical trials in the field have been published. This document provides a focused updated of the 2018 recommendations. The group recommends that in patients with atrial fibrillation undergoing PCI, a non-vitamin K antagonist oral anticoagulant is the oral anticoagulation of choice. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor should be given to all patients during the peri-PCI period (during inpatient stay, until time of discharge, up to 1 week after PCI, at the discretion of the treating physician), after which the default strategy is to stop aspirin and continue treatment with a P2Y12 inhibitor, preferably clopidogrel, in combination with a non-vitamin K antagonist oral anticoagulant (ie, double therapy). In patients at increased thrombotic risk who have an acceptable risk of bleeding, it is reasonable to continue aspirin (ie, triple therapy) for up to 1 month. Double therapy should be given for 6 to 12 months with the actual duration depending on the ischemic and bleeding risk profile of the patient, after which patients should discontinue antiplatelet therapy and receive oral anticoagulation alone.
引用
- Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. Circulation. 2021. PMID: 33555916. doi:10.1161/CIRCULATIONAHA.120.050438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。